Brest

• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting
  2024-514327-42-00 4 2025-12-18 Advanced neuroendocrine carcinomas (NECs) of the digestive system or u
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• Phase 2a Study of VX-407 in Subjects with ADPKD Who Have a Subset of PKD1 Gene Variants Recruiting
  2024-517393-13-00 4 2025-12-02 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm … Recruiting
  2025-521268-37-00 6 2025-11-25 Respiratory tract diseases
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec … Recruiting
  2025-520582-51-00 5 2025-10-17 Hormone receptor positive breast cancer
• A phase Ib, open-label, ascending dose study to assess safety, tolerability and pharmacokinetics of PIT565 in participants with rheumatoid a … Recruiting
  2024-520196-27-00 3 2025-10-01 Rheumatoid Arthritis
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 5 2025-09-23 Advanced HER2-expressing Biliary Tract Cancer
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting
  2024-516233-12-00 3 2025-08-08 Advanced pancreatic adenocarcinoma
• A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease Recruiting
  2025-521462-96-00 3 2025-08-05 Sjogren's Disease
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting
  2023-506537-29-00 5 2025-02-24 Haemophilia A
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al … Recruiting
  2024-517004-11-00 5 2024-10-22 Chronic pulmonary aspergillosis
• Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting
  2024-513219-29-00 5 2024-10-21 Renal Cell Carcinoma
• A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c … Recruiting
  2023-505606-42-00 5 2024-10-15 Head and Neck Squamous Cell Carcinoma (HNSCC)
• A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting
  2023-507555-29-00 9 2024-08-16 LA/mGC/GEJC (locally advanced unresectable or metastatic gastric cance
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting
  2023-503699-25-00 5 2024-07-15 Progressive Pulmonary Fibrosis
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting
  2023-510275-64-00 9 2023-05-31 Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or ot
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections

Showing 73–96 of 490 trials